Development
Revolution Medicines' daraxonrasib nearly doubles OS in Phase III pancreatic cancer trial
Revolution Medicines (Nasdaq: RVMD) reported that daraxonrasib nearly doubled median overall survival compared with standard chemotherapy in previously...
Eli Lilly's Jaypirca beats venetoclax-rituximab in Phase III for previously treated CLL
Eli Lilly (NYSE: LLY) reported that pirtobrutinib (Jaypirca) added to venetoclax and rituximab produced a statistically significant improvement in...
Allogene's off-the-shelf CD19 CAR-t clears MRD benchmark in Phase II LBCL trial
Allogene Therapeutics (Nasdaq: ALLO) reported interim futility data from its Phase II ALPHA3 trial showing that cemacabtagene ansegedleucel (cema-cel)...
Ideaya and Servier's darovasertib plus crizotinib meets Phase II/III endpoint in metastatic uveal melanoma
IDEAYA Biosciences (NASDAQ: IDYA) and Servier reported that darovasertib plus crizotinib met the primary endpoint of the Phase II/III OptimUM-02 trial,...
Diamyd considering options after Phase III failure for retogatein in type 1 diabetes
Diamyd Medical (Sweden) has terminated the Phase 3 DIAGNODE-3 trial of retogatein (rhGAD65), an antigen-specific immunotherapy for Stage 3 type 1 diabetes,...
MacroGenics' lorigerlimab resumes Phase II enrollment for gynecologic cancers after FDA hold lifted
MacroGenics, the Rockville, Maryland-based biopharmaceutical company, announced on April 8, 2026 that the US FDA has removed a partial clinical hold on the...
CMS advances INHBE-targeting siRNA into first-in-human obesity study
China Medical System Holdings (HKEX: 00867), a Shenzhen-based specialty pharmaceutical company historically known for in-licensing and commercialising drugs...
Zentalis' azenosertib advances in cyclin E1-positive platinum-resistant ovarian cancer trial
Zentalis Pharmaceuticals announced on April 9 that a prespecified interim analysis from Part 2a of the DENALI trial has identified 400mg once daily on a...
Sunho's ISH0613 bispecific antibody enters Phase Ia for systemic lupus erythematosus
SUNHO (China) BioPharmaceutical has registered a Phase Ia first-in-human clinical trial for ISH0613, an internally developed bifunctional bispecific...
Luye Pharma starts China Phase II for TAAR1/5-HT2CR dual agonist in schizophrenia
Luye Pharma announced on April 8 that the first subject has been enrolled in the Phase II clinical trial in China of LY03020, an oral controlled-release...
Insmed discontinues brensocatib development in hidradenitis suppurativa after CEDAR study fail
Insmed Discontinues Brensocatib HS Program After CEDAR Study Fails to Beat Placebo
Alzheon doses oral amyloid oligomer inhibitor with APOE4 corrector function in Alzheimer's
Alzheon has dosed the first human subjects in a Phase 1 trial of ALZ-507, an oral small molecule designed to inhibit the formation of neurotoxic soluble...
Hemispherian's GLIX1 initiates Phase I/IIa trial in recurrent glioblastoma patients
Hemispherian AS, an Oslo-based oncology company, announced the initiation of a first-in-human Phase I/2a GLIX1 clinical trial in glioblastoma on April 8,...
Corbus agrees with FDA on Phase III direction of CSPC-licensed Nectin-4 ADC
Corbus Pharmaceuticals (Nasdaq: CRBP) announced that the FDA has aligned with its proposed registrational study designs for CRB-701, a Nectin-4–targeting...
Airna's RNA-editing therapy targets PiZ mutation in alpha-1 antitrypsin deficiency via ADAR recruitment
AIRNA doses first patient in Phase 1 trial of AIR-001, an RNA-editing therapy for alpha-1 antitrypsin deficiency
The AllSci Brief
Systematic R&D and deal news. Daily.